Boyu Hu
Rating: 4.9 of 5
( out of 83 reviews )

Boyu Hu, MD

Languages spoken: English

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

2D, Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
801-585-2626
Get Directions

  • Dr. Boyu Hu is an Associate Professor of Medicine and the Director of Lymphoma and Chronic Lymphocytic Leukemia (CLL) within the Division of Hematology and Hematologic Malignancies at the Huntsman Cancer Institute/University of Utah. He specializes in treating and performing research in patients with lymphoid malignancies (i.e. non-Hodgkin lymphoma and Hodgkin lymphoma) and CLL. He is primarily a clinical researcher and has been the principal investigator on over 20 phase I, II and III clinical trials investigating novel treatments and combination therapies for patients diagnosed with lymphoma and CLL. His contributions to the field have led to the direct FDA approval and development of targeted therapies, bispecific antibodies and chimeric antigen receptor T-cell therapies. Nationally, he serves as a member and the Huntsman Cancer Institute representative for the National Comprehensive Cancer Network B-cell Lymphoma Guidelines committee. Furthermore, he is an active participant within the Southwest Oncology Group and the National Clinical Trials Network. He is currently the co-chair and national principal investigator for AHOD2131, which is a randomized phase III clinical trial investigating the incorporation of novel immuno-oncology agents for the treatment of early stage Hodgkin lymphoma.

    To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Specialties

    Board Certification

    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    American Board of Internal Medicine

    Patient Rating

    Rating: 4.9 out of 5
    4.9 /5
    ( out of 83 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    An excellent doctor.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Incredible knowledge. Caring

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Hu has given my wife and myself a very good understanding and outlook on my condition

    Huntsman Cancer Institute
    Rating: 5 out of 5

    Good

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He is generous with his time. He is gracious. He listens. He is open to medical questions outside his specialty. He explains complicated issues in layman's terms. He is respectful of me. I feel that he is in my ¿corner¿. He is wise beyond his years.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    I couldn't have asked for a better doctor than Dr. Hu! He fosters meaningful relationships with his patients and helps them to live their best life

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    I have had a few friends that got cancer and I told all of them go to the Huntsman. If your lucky you get Dr. Hu for your Oncologist

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Nothing but good news so far

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    I met Dr. Hu 4 years ago and he has been my physician who devised the chemotherapy plan for a rare lymphoma present in an abnormal manifestation. He is a very bright and talented physician; honest and forthright with his patients. He has a personal manner and takes personal interest in them. Without this treatment I would have succumbed to the aggressive lymphoma three and a half years ago. I have had a great experience with him and highly recommend him as an expert physician!

  • Dr. Boyu Hu is an Associate Professor of Medicine and the Director of Lymphoma and Chronic Lymphocytic Leukemia (CLL) within the Division of Hematology and Hematologic Malignancies at the Huntsman Cancer Institute/University of Utah. He specializes in treating and performing research in patients with lymphoid malignancies (i.e. non-Hodgkin lymphoma and Hodgkin lymphoma) and CLL. He is primarily a clinical researcher and has been the principal investigator on over 20 phase I, II and III clinical trials investigating novel treatments and combination therapies for patients diagnosed with lymphoma and CLL. His contributions to the field have led to the direct FDA approval and development of targeted therapies, bispecific antibodies and chimeric antigen receptor T-cell therapies. Nationally, he serves as a member and the Huntsman Cancer Institute representative for the National Comprehensive Cancer Network B-cell Lymphoma Guidelines committee. Furthermore, he is an active participant within the Southwest Oncology Group and the National Clinical Trials Network. He is currently the co-chair and national principal investigator for AHOD2131, which is a randomized phase III clinical trial investigating the incorporation of novel immuno-oncology agents for the treatment of early stage Hodgkin lymphoma.

    To schedule an appointment: New Patients: 801-585-6906 Returning Patients: 801-585-2626 or schedule through MyChart.

    For questions regarding our clinical programs or for help identifying the right Hematology specialist for you or for your family member, please feel free to contact our Clinical Care Specialist (801) 587-4630.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Associate Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Sub: Hematology)
    American Board of Internal Medicine (Sub: Medical Oncology)
    American Board of Internal Medicine

    Education history

    Undergraduate Duke University B.S.
    Professional Medical Medicine - Case Western Reserve University School of Medicine M.D.
    Internship Internal Medicine - Hospital of the University of Pennsylvania Intern
    Residency Internal Medicine - Hospital of the University of Pennsylvania Resident
    Fellowship Hematology/Oncology - University of Texas MD Anderson Cancer Center Fellow

    Selected Publications

    Journal Article

    1. Hu B, Takahashi K, et al (2018). Clinical Implications of Cancer Gene Mutations in Patients with Chronic Lymphocytic Leukemia Treated with Lenalidomide. Blood, 131(16), 1820-32.
    2. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kangal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson, P, Burger J, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG (2019). Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol, 185(5), 852-864.
    3. Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kangal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson, P, Burger J, Jain N, Ferrajoli A, Bose P, Estov Z, Keating M, Wierda WG (2019). Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol, 187(3), 307-318.
    4. Hu Z, Hu B, Collins J (2007). Prediction of synergistic transcription factors by function conservation. Genome biology, 8(12), R257. (Read full publication)
    5. Dave H, Terpilowski M, Mai M, Toner K, Grant M, Stanovich M, Lazarski C, Shibli A, Maglo P, Hog F, Schore R, Glenn M, Hu B, Hanley P, Ambinder R, Bollard C (2021). Tumor associated antigen specific T cells with nivolumab are safe and persist in vivo in rel/ref Hodgkin Lymphoma. Blood advances, 6, 473-485. (Read full publication)
    6. Feusier JE, Madsen MJ, Avery BJ, Williams JA, Stephens DM, Hu B, Osman AEG, Glenn MJ, Camp N (2021). Shared genomic segment analysis in a large high-risk chronic lymphocytic leukemia pedigree implicates CXCR4 in inherited risk. Journal of translational genetics and genomics, 5, 189-199. (Read full publication)
    7. Fenlon JB, Hutten RJ, Johnson SB, Hu B, Shah H, Stephens DM, Maity A, Gaffney DK, Tao (2023). Evaluating patterns of care for early-stage low-grade follicular lymphoma in the rituximab era. Leukemia & Lymphoma, 64(2), 356-363. (Read full publication)
    8. Rock CB, Chipman JJ, Parsons MW, Weil CR, Hutten RJ, Tao R, Tward JD, Shah HR, Hu B, Stephens DM, Gaffney D (2022). Second Primary Malignancies in Diffuse Large B-cell Lymphoma Survivors with 40 Years of Follow Up: Influence of Chemotherapy and Radiation Therapy. Advances in radiation oncology, 7(6), 101035. (Read full publication)
    9. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach J (2022). Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical cancer research, 28(15), 3242-3247. (Read full publication)
    10. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens D (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. American journal of hematology, 98(7), E172-E174.
    11. Ermann DA, Vardell VA, Shah H, Fitzgerald L, Tao R, Gaffney DK, Stephens DM, Hu (2023). Survival Outcomes of Limited-Stage Diffuse Large B-Cell Lymphoma Treated With Radiation Therapy. Clinical lymphoma, myeloma & leukemia, 24(2), 94-104.e6. (Read full publication)
    12. Azim A, Hu B, Gilligan S, Sarwal A, Hartsell S, Pandya V, Raphael K (2023). How I Evaluate a High Anion Gap Metabolic Acidosis. Clinical journal of the American Society of Nephrology, 19(4), 525-527. (Read full publication)
    13. Bowers JT, Anna J, Bair SM, Annunzio K, Epperla N, Pullukkara JJ, Gaballa S, Spinner MA, Li S, Messmer MR, Nguyen J, Ayers EC, Wagner CB, Hu B, Di M, Huntington SF, Furqan F, Shah NN, Chen C, Ballard HJ, Hughes ME, Chong EA, Nasta SD, Barta SK, Landsburg DJ, Svoboda (2023). Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort. Blood advances, 7(21), 6630-6638. (Read full publication)
    14. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Kaminski MS, Karimi Y, Kelsey CR, King R, Krivacic S, LaCasce AS, Lim M, Messmer M, Narkhede M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Smith SD, Svoboda J, Swinnen LJ, Tuscano J, Vose JM, Dwyer MA, Sundar (2023). NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. Journal of the National Comprehensive Cancer Network, 21(11), 1118-1131. (Read full publication)
    15. Wagner CB, Boucher K, Nedved A, Micallef IN, Desai S, Hatic H, Goyal G, Zacholski E, Fegley A, Sigmund AM, Bond DA, Samuels C, Kamdar MK, Ba Aqeel S, Torka P, MacDougall K, Borogovac A, Rajeeve S, Sundaram S, Fedak K, Modi D, Travers E, Ayyappan S, Chilakamarri N, Brem EA, Ermann DA, Fitzgerald LA, Hu B, Stephens DM, Shah (2023). Effect of cumulative dose of brentuximab vedotin maintenance in relapsed/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes. Haematologica, 108(11), 3025-3032. (Read full publication)
    16. Parsons MW, Rock C, Chipman JJ, Shah HR, Hu B, Stephens DM, Tao R, Tward JD, Gaffney D (2023). Secondary malignancies in non-Hodgkin lymphoma survivors: 40¿years of follow-up assessed by treatment modality. Cancer medicine, 12(3), 2624-2636. (Read full publication)
    17. Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Hodgson D, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum K, Perry AM, Kovach A, Constine LS, Shields LK, Prica A, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg J (2023). 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023. Hematological oncology, 41 Suppl 2, 33-35. (Read full publication)
    18. Herrera AF, LeBlanc M, Castellino SM, Li H, Rutherford SC, Evens AM, Davison K, Punnett A, Parsons SK, Ahmed S, Casulo C, Bartlett NL, Tuscano JM, Mei MG, Hess BT, Jacobs R, Saeed H, Torka P, Hu B, Moskowitz C, Kaur S, Goyal G, Forlenza C, Doan A, Lamble A, Kumar P, Chowdhury S, Brinker B, Sharma N, Singh A, Blum KA, Perry AM, Kovach A, Hodgson D, Constine LS, Shields LK, Prica A, Dillon H, Little RF, Shipp MA, Crump M, Kahl B, Leonard JP, Smith SM, Song JY, Kelly KM, Friedberg J (2024). Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma. The New England journal of medicine, 391(15), 1379-1389. (Read full publication)
    19. Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers E (2024). Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers. Haematologica, 110(3), 0. (Read full publication)
    20. Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, Hu B, Beitinjaneh A, Weng WK, Kim YH, Khodadoust MS, Huen AO, Williams LM, Ma A, Huang E, Ganpule A, Nagar SD, Sripakdeevong P, Cullingford EL, Karnik S, Dequeant ML, Patel JN, He XS, Li Z, He QA, Mendonez JH, Keegan A, Horwitz S (2024). Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. The Lancet. Oncology, (Read full publication)
    21. Pierce AL, Okcu I, Nowakowski G, Tolu S, Amengual J, Ross C, Graber J, Bock A, Hu B, Ermann (2025). HSR25-185: A Multicenter Retrospective Study of Treatment and Survival Outcomes of Patients With Secondary CNS Relapsed DLBCL in the Modern Era. Journal of the National Comprehensive Cancer Network, 23(3.5), (Read full publication)
    22. Baron K, Anto E, Esther J, Vardell VA, Pappas L, Bock A, Ermann DA, Fitzgerald LA, Hu B, Shah H (2025). Comparison of Real-World Outcomes in Patients With Follicular Lymphoma Treated With BR Versus RCHOP-Like Regimens. Clinical lymphoma, myeloma & leukemia, (Read full publication)
    23. Brooks TR, Zabor EC, Bedelu Y, Yang X MD, Karimi YH, Nedved AN, Wang Y, Dave NK, Landsburg DJ, Baron K, Hu B, Trotier D, Pophali PA, Miller J PharmD, Grover NS, Reinert C, Major A, Schwarz T, Patel K, Salafian K MD, Ayers EC, Sundaram S, Brody JD, McKenna M, Tiger YKR, Sears-Smith M, Ghosh N, Peterson C DO, Khan C, Bliven SP MD, Narkhede M, Gibson A, Kline J, Munoz J, Garza Morales R, Ho C, Smith SD, Niu A MD, Hernandez-Ilizaliturri FJ, Chinyengetere F MDPhD, Dave SS, Abdel-Razeq N, Alhaj Moustafa M, Caimi P, Hill B (2025). Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab. Blood, (Read full publication)
    24. Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, DeVos S, Dholaria B, Fayad LE, Habermann TM, Hamid MS, Hernandez-Ilizaliturri F, Hu B, Karimi Y, Kelsey CR, King R, Kline J, Krivacic S, LaCasce AS, Landsburg D, Lim M, Messmer M, Rabinovitch R, Ramakrishnan P, Reid E, Roberts KB, Saeed H, Saito NG, Smith SD, Swinnen LJ, Tuscano J, Vose JM, Dwyer M, Sundar (2025). NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025. Journal of the National Comprehensive Cancer Network, 23(10), (Read full publication)
    25. Lo AC, Milgrom SA, Vega RM, Hodgson D, Chapman H, Kessel S, Cho SY, Schoder H, Mhlanga J, Pandit-Taskar N, Lai H, Gowdy C, Qi J, Abu-Ata N, Hu B, Seelisch J, Keller F, Castellino SM, LaCasce A, Grover N, Evens A, DuVall A, Allen P, Renfro LA, Wu Y, Kelly KM, Hoppe B (2025). Enhancing Radiotherapy Quality Assurance in Lymphoma: A Rigorous Real-Time Central Review Process in AHOD2131. International journal of radiation oncology, biology, physics, (Read full publication)

    Review

    1. Hu B, Oki (2018). Novel Immunotherapy Options for Extranodal NK/T-cell Lymphoma. Frontiers in oncology, 8(139),

    Case Report

    1. Hu B, Patel JL, Tao R, Cannon RB, Monroe M, Goyal (2022). Near Complete Response to Trametinib Treatment in Histiocytic Sarcoma Harboring a Somatic KRAS Mutation. Journal of the National Comprehensive Cancer Network, 20(6), 1-4. (Read full publication)
    2. Gociman S, Baron K, Hu B, Zussman J, Madigan L (2022). Blistering Lesions Associated With Loncastuximab Tesirine. JAMA dermatology, 158(7), 831-832. (Read full publication)

    Letter

    1. Vardell VA, Ermann DA, Fitzgerald L, Shah H, Hu B, Stephens D (2024). T-cell prolymphocytic leukemia: Epidemiology and survival trends in the era of novel treatments. American journal of hematology, 99(3), 494-496. (Read full publication)
    2. Vardell VA, Ermann DA, Fitzgerald LA, Shah HR, Hu B, Stephens D (2023). Influence of racial and ethnic identity on overall survival in patients with chronic lymphocytic leukemia. American journal of hematology, 98(7), E172-E174. (Read full publication)